Gemcitabine and Thymosin Alpha 1 Combo Shows Stronger Anti-Tumor Effect in NK/T-Cell Lymphoma

Nasal Natural Killer/T-cell Lymphoma (NNKTL) is a rare and aggressive type of non-Hodgkin lymphoma, particularly prevalent in Asia and Latin America. It often presents with advanced disease and has a notoriously poor prognosis, with current treatment options like chemotherapy and radiotherapy frequently leading to relapse or insufficient long-term survival. There is an urgent and critical need for novel therapeutic strategies to improve patient outcomes. This study specifically addresses the knowledge gap regarding the potential synergistic benefits of combining conventional chemotherapy with immunomodulatory peptides for NNKTL treatment.

The combination of Gemcitabine and Thymosin alpha 1 demonstrated significantly enhanced anti-tumor effects compared to either agent alone. In vitro, the combination treatment resulted in a 43% reduction in cell viability and a 2.5-fold increase in apoptosis compared to Gemcitabine monotherapy (p<0.001). In vivo, xenograft tumors in the combination group exhibited a 78% reduction in tumor volume compared to the control group (p<0.0001), and a 35% greater reduction than Gemcitabine alone (p<0.01). This synergistic effect was attributed to enhanced cell cycle arrest and increased programmed cell death. Furthermore, the combination therapy significantly suppressed the expression of key proliferative markers by 60% and increased pro-apoptotic protein levels by 3.1-fold compared to single-agent treatments. This robust anti-tumor activity suggests a powerful therapeutic synergy. The most significant finding was that the combined therapy of Gemcitabine and Thymosin alpha 1 led to a 2.8-fold increase in overall survival rate in the mouse model compared to Gemcitabine monotherapy, highlighting a powerful synergistic anti-lymphoma effect.